Single-cell RNA-seq of LNCaP prostate cancer cells treated with Enzalutamide and Tazemetostat under hypoxic conditions

This experiment investigates the transcriptional landscape of LNCaP prostate cancer cells in response to hormonal and epigenetic therapy under hypoxic conditions using single-cell RNA sequencing (scRNA-seq). The study aims to model drug resistance mechanisms by exposing cells to chronic hypoxia and treating them with Enzalutamide, an androgen receptor inhibitor, with and without Tazemetostat, an EZH2 inhibitor. Cells were sampled across multiple time points to identify resistant clones and assess how combination therapy alters gene expression. This experiment provides insight into the gene expression signatures associated with resistance and explores potential biomarkers relevant to advanced prostate cancer progression.